CIK 0001517022 · Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208756903
- Phone
- 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 34 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-06-15 | Satter Muneer A Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 | ||
| 2017-06-15 | Canute Scott A Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 | ||
| 2017-06-15 | Clayman Michael D. Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 | ||
| 2017-06-15 | Nash Duane Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 | ||
| 2017-06-15 | GOWEN MAXINE Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 | ||
| 2017-06-15 | WYZGA MICHAEL S Director | Grant or award · Stock Option (Right to buy) | +12,500 | 12,500 | ||
| 2017-05-31 | Jain Rita SVP, Chief Medical Officer | Grant or award · Stock Option (Right to buy) | +200,000 | 200,000 | ||
| 2017-04-03 | Dahan Michel SVP, Chief Business Officer | Sale | −1,401 | $9.18 | $13K | 108,623 |
| 2017-04-03 | Nash Duane Director | Sale | −991 | $9.20 | $9K | 24,677 |
| 2017-04-03 | Hadas Nicole R. SVP, General Counsel, Sec. | Sale | −1,556 | $9.18 | $14K | 109,856 |
| 2017-02-21 | Dahan Michel SVP, Chief Business Officer | Grant or award | +39,500 | 110,024 | ||
| 2017-02-21 | Dahan Michel SVP, Chief Business Officer | Grant or award · Stock Option (Right to buy) | +62,500 | $10.14 | $634K | 62,500 |
| 2017-02-21 | Tubridy Karen L SVP, Chief Development Officer | Grant or award | +23,000 | 23,000 | ||
| 2017-02-21 | Tubridy Karen L SVP, Chief Development Officer | Grant or award · Stock Option (Right to buy) | +36,500 | $10.14 | $370K | 36,500 |
| 2017-02-21 | Maroni Bradley SVP and Chief Medical Officer | Grant or award | +23,500 | 64,585 | ||
| 2017-02-21 | Maroni Bradley SVP and Chief Medical Officer | Grant or award · Stock Option (Right to buy) | +37,500 | $10.14 | $380K | 37,500 |
| 2017-02-21 | Hadas Nicole R. SVP, General Counsel, Sec. | Grant or award | +28,500 | 111,412 | ||
| 2017-02-21 | Hadas Nicole R. SVP, General Counsel, Sec. | Grant or award · Stock Option (Right to buy) | +45,000 | $10.14 | $456K | 45,000 |
| 2017-02-21 | Butler John P. CEO and President | Grant or award | +119,500 | 317,780 | ||
| 2017-02-21 | Butler John P. CEO and President | Grant or award · Stock Option (Right to buy) | +190,000 | $10.14 | $1.9M | 190,000 |
Page 23 of 27 · 537 trades